Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report)’s share price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.20 and traded as high as $0.38. Sonoma Pharmaceuticals shares last traded at $0.32, with a volume of 668,763 shares changing hands.
Sonoma Pharmaceuticals Stock Down 9.3 %
The company has a market cap of $6.10 million, a PE ratio of -0.44 and a beta of 1.37. The company’s fifty day moving average is $0.27 and its 200-day moving average is $0.20.
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last issued its quarterly earnings data on Monday, June 17th. The company reported ($0.07) EPS for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 64.15% and a negative net margin of 37.97%. The firm had revenue of $3.44 million during the quarter. Equities research analysts expect that Sonoma Pharmaceuticals, Inc. will post -0.2 EPS for the current fiscal year.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
Read More
- Five stocks we like better than Sonoma Pharmaceuticals
- What Makes a Stock a Good Dividend Stock?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- How to Invest in the FAANG Stocks
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Quiet Period Expirations Explained
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.